TRAW
Traws Pharma, Inc. NASDAQ$1.49
Mkt Cap $12.5M
52w Low $0.97
22.6% of range
52w High $3.27
50d MA $1.66
200d MA $1.88
P/E (TTM)
1.8x
EV/EBITDA
-0.3x
P/B
—
Debt/Equity
0.0x
ROE
79.2%
P/FCF
-0.4x
RSI (14)
—
ATR (14)
—
Beta
1.62
50d MA
$1.66
200d MA
$1.88
Avg Volume
156.5K
About
Traws Pharma, Inc., a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; a…
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | 1M% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 15, 2026 | AMC | -0.92 | -0.82 | +10.9% | 1.23 | +1.6% | -1.6% | +1.6% | +13.0% | +4.1% | +4.9% | — | — |
| Nov 13, 2025 | AMC | -9.16 | -0.34 | +96.3% | 1.77 | -1.1% | +22.6% | +17.5% | +20.3% | +19.2% | +20.9% | +26.6% | — |
| Aug 14, 2025 | AMC | -8.75 | -0.11 | +98.7% | 1.62 | +0.6% | -6.8% | -12.3% | -17.3% | -17.9% | -14.8% | +27.8% | — |
| May 15, 2025 | AMC | -8.04 | 2.09 | +126.0% | 1.10 | -1.8% | +8.2% | +21.8% | +13.6% | +9.1% | +14.5% | +48.2% | — |
| Mar 31, 2025 | AMC | -9.55 | 95.66 | +1101.7% | 2.30 | -2.6% | -7.0% | +0.9% | -5.2% | -14.8% | -17.4% | -37.0% | — |
| Nov 14, 2024 | AMC | -6.25 | -8.81 | -41.0% | 5.58 | -4.8% | -10.6% | -11.6% | -15.8% | -19.5% | -19.2% | -15.8% | — |
| Aug 15, 2024 | AMC | -6.25 | -121.75 | -1848.0% | 9.00 | +3.1% | +6.7% | +7.0% | +0.0% | +1.7% | -1.3% | -5.6% | — |
| May 15, 2024 | AMC | -6.00 | -6.00 | +0.0% | 16.43 | +0.4% | -2.2% | -2.5% | -2.7% | -0.6% | -1.8% | -8.6% | — |
| Apr 1, 2024 | AMC | -0.25 | -0.19 | +24.0% | 25.00 | +0.0% | -0.5% | -14.3% | -16.4% | -19.2% | -21.6% | -34.0% | — |
| Nov 14, 2023 | AMC | -0.26 | -0.23 | +11.5% | 16.50 | +1.5% | -4.5% | -4.5% | -1.5% | +0.0% | -3.0% | +13.6% | — |
Recent Filings
8-K · 7.01
! Medium
Unknown — 8-K 7.01: Regulation FD Disclosure
This boilerplate forward-looking statement disclaimer suggests TRAW lacks concrete news to announce, signaling management uncertainty about near-term performance and offering minimal investment insight.
Apr 15
8-K · 1.01
! Medium
Unknown — 8-K 1.01: Equity Issuance
TRAW's dilutive equity issuance to an irrevocable holder signals potential capital raising or debt restructuring that will immediately reduce earnings per share and existing shareholder value.
Apr 15
NT 10-K
!!! Very High
Unknown — Late Annual Report — Distress Signal
TRAW's late annual report filing signals potential financial or operational distress, creating regulatory risk and likely triggering delisting concerns that could severely impair shareholder value.
Mar 31
8-K · 8.01
!! High
Traws Pharma, Inc. -- 8-K 8.01: Material Event / Announcement
Traws Pharma filed a press release via 8-K but the summary lacks specific deal details, making it impossible to assess investor impact without reviewing the full exhibit.
Feb 19
Data updated apr 27, 2026 5:29am
· Source: massive.com